Mark Woodward Selected Research

Vascular Diseases (Vascular Disease)

2/2022	Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes.
1/2022	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE.
3/2021	Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes.
1/2021	Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial.
1/2021	History of lower-limb complications and risk of cancer death in people with type 2 diabetes.
1/2021	The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial.
12/2020	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
1/2020	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
1/2020	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study.
1/2020	Observational analyses from ADVANCE and ADVANCE-ON.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Woodward Research Topics

Disease

69	Type 2 Diabetes Mellitus (MODY) 02/2022 - 06/2008
65	Stroke (Strokes) 04/2022 - 05/2003
65	Vascular Diseases (Vascular Disease) 02/2022 - 06/2003
51	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 07/2003
46	Hypertension (High Blood Pressure) 05/2022 - 10/2003
27	Coronary Disease (Coronary Heart Disease) 03/2020 - 05/2003
25	Ischemic Stroke 01/2022 - 09/2005
23	Myocardial Infarction 12/2022 - 07/2005
21	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020 - 05/2003
17	Albuminuria 01/2021 - 01/2011
16	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 01/2011
14	Diabetes Mellitus 01/2022 - 03/2008
14	Inflammation (Inflammations) 01/2019 - 07/2003
11	Heart Failure 10/2020 - 01/2005
10	Chronic Renal Insufficiency 09/2021 - 06/2009
10	Cerebral Hemorrhage 01/2021 - 02/2010
9	Transient Ischemic Attack 11/2021 - 05/2003
8	Atherosclerosis 01/2017 - 06/2010
7	Renal Insufficiency (Renal Failure) 01/2022 - 06/2012
7	Kidney Diseases (Kidney Disease) 01/2022 - 06/2012
7	Dementia (Dementias) 01/2022 - 05/2003
7	Diabetic Nephropathies (Diabetic Nephropathy) 03/2021 - 06/2012
7	Body Weight (Weight, Body) 01/2020 - 01/2015
6	Diabetes Complications 10/2021 - 02/2010
6	Neoplasms (Cancer) 01/2021 - 08/2012
5	Infections 01/2022 - 01/2017
5	Obesity 01/2021 - 09/2007
5	Peripheral Arterial Disease 01/2020 - 10/2007
5	Proteinuria 01/2017 - 06/2012
4	Cognitive Dysfunction 12/2022 - 05/2003
4	IGA Glomerulonephritis (IGA Nephropathy) 01/2022 - 06/2012
4	Chronic Disease (Chronic Diseases) 10/2021 - 02/2014
4	Atrial Fibrillation 11/2020 - 10/2005
4	Noncommunicable Diseases 01/2018 - 02/2014
4	Overweight 01/2018 - 09/2007
3	Heart Diseases (Heart Disease) 04/2022 - 02/2003
3	Necrosis 02/2021 - 06/2008
3	Pain (Aches) 01/2021 - 09/2006
3	Stillbirth 03/2020 - 01/2017
3	Spontaneous Abortion (Miscarriage) 03/2020 - 01/2017
3	Hemorrhage 04/2016 - 09/2006

Drug/Important Bio-Agent (IBA)

59	Gliclazide (Diamicron)IBA 02/2022 - 06/2008
58	perindopril drug combination indapamideIBA 02/2022 - 04/2009
41	Perindopril FDA LinkGeneric 01/2022 - 05/2003
29	Glucose (Dextrose)FDA LinkGeneric 10/2021 - 08/2006
28	CholesterolIBA 01/2022 - 06/2003
28	CreatinineIBA 01/2021 - 01/2011
23	Indapamide FDA LinkGeneric 12/2022 - 05/2003
21	AlbuminsIBA 03/2021 - 01/2011
21	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2006
19	LipidsIBA 01/2022 - 09/2005
17	HDL CholesterolIBA 01/2020 - 05/2003
15	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 07/2015
15	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 10/2005
13	Antihypertensive Agents (Antihypertensives)IBA 12/2022 - 06/2010
12	Fibrinogen (Factor I)FDA Link 04/2022 - 02/2003
12	C-Reactive ProteinIBA 01/2021 - 07/2003
10	SaltsIBA 05/2022 - 02/2014
10	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2017 - 01/2005
9	pro-brain natriuretic peptide (1-76)IBA 07/2020 - 01/2005
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 09/2003
8	SodiumIBA 01/2020 - 10/2011
7	DiureticsIBA 01/2020 - 01/2004
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 05/2015
6	Triglycerides (Triacylglycerol)IBA 01/2019 - 05/2003
6	Troponin T (Troponin T1)IBA 01/2017 - 01/2014
5	Pharmaceutical PreparationsIBA 12/2022 - 11/2013
5	Cystatin CIBA 12/2020 - 06/2009
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 04/2011
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2009
5	Biological ProductsIBA 01/2019 - 06/2011
5	Interleukin-6 (Interleukin 6)IBA 01/2017 - 07/2003
5	Advanced Glycation End ProductsIBA 10/2015 - 06/2012
5	Interleukin-18 (Interleukin 18)IBA 07/2011 - 06/2008
4	Dietary SodiumIBA 05/2022 - 12/2014
4	LDL CholesterolIBA 01/2022 - 12/2007
4	omega-Chloroacetophenone (Mace)IBA 01/2019 - 04/2009
4	CalciumIBA 01/2019 - 03/2009
4	dalcetrapibIBA 01/2016 - 08/2011
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 06/2008
3	Methylprednisolone FDA LinkGeneric 01/2022 - 01/2017
3	oxidized low density lipoproteinIBA 01/2022 - 12/2007
3	SteroidsIBA 01/2021 - 06/2012
3	TroponinIBA 07/2020 - 09/2017
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020 - 06/2008
3	Bicarbonates (Hydrogen Carbonate)IBA 01/2020 - 07/2011
3	PotassiumIBA 12/2019 - 12/2018
3	CotinineIBA 09/2017 - 05/2003
3	Retinaldehyde (Retinal)IBA 01/2017 - 01/2016
3	Receptor for Advanced Glycation End ProductsIBA 10/2015 - 04/2014
3	AntioxidantsIBA 05/2015 - 01/2009

Therapy/Procedure

35	Therapeutics 12/2022 - 05/2003
6	Glycemic Control 01/2020 - 06/2008
5	Contraindications 01/2019 - 06/2006
4	Secondary Prevention 01/2022 - 10/2007
4	Kidney Transplantation 01/2021 - 03/2013
4	Surgical Amputation (Amputations) 01/2020 - 01/2016
4	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2019 - 11/2012
3	Length of Stay 01/2022 - 02/2009
3	Light Coagulation 01/2017 - 01/2016